Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.

Emmanuel S Antonarakis,Sumit K Subudhi,Christopher M Pieczonka,Lawrence I Karsh,David I Quinn,Jason M Hafron, Helen M Wilfehrt,Matthew Harmon,Nadeem A Sheikh,Neal D Shore,Daniel P Petrylak

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览22

暂无评分

摘要

Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.

查看译文

关键词

prostate cancer,enzalutamide,castration-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要